The evolution of the pharmaceutical industry in the country takes place in several stages, from the primary import of medicines to the development of domestic production, the growth of R & D potential and the introduction of innovative products on the market.Many countries, taking into account global trends of population growth and aging, are pursuing a policy of supporting their own pharmaceutical industry. And as the transition to an innovative development path takes more than a decade, due to the long process of commercialization of new drugs (from development to market launch), the development of the generic and contract manufacturing market takes precedence.
Ukraine is currently in a transitional phase: on the one hand a production base has been created in recent years, domestic companies have modernized and become able to produce analogues of innovative drugs; on the other — the transition to an innovative development path has just begun, and so far the shortage of breakthrough domestic developments is evident.With the increase in global spending on health, states are optimizing their budgets and reorienting consumption towards cheaper generic drugs, that is why this segment demonstrates one of the fastest growing rates. The world market for generics amounted to 331 billion dollars in 2015, and the projected growth rate to 2020 — an average of 11% per year.
Thus, the volume of sales by 2020 will exceed $ 500 billion.A significant driver of market growth will be the second wave of expiration of patents for drugs with a large volume of sales. According to Evaluate Pharma, in 2016-2022 patent protection may lose the drugs, that have the annual total sales around $ 250 billion. If developed markets are close to saturation (in the United States, generics account for up to 85% of all prescription drugs), then in developing countries such as India, China and the ASEAN countries, there is a significant unrealized potential for increasing the consumption of generics.Thus, in the next 5 years, a significant increase in the share of developing countries in the generic market is expected. If in 2015 the share of the United States and the five largest economies of Europe (Great Britain, Germany, France, Italy and Spain) was 41.8%, then by 2020 their share will decrease to 35.5%.
Source: open foreign sourcesа.
Свежие комментарии